273) h but had similar transfection efficiency compared to its parent plasmid (pEGFP-N2). |
274) achieves stronger platelet inhibition as compared to its predecessor clopidogrel. |
275) gs with primary appendicular bone tumours compared to long bone survey radiography, |
276) onfer improved mid- and long-term patency compared to long saphenous veins. |
277) can origin reported higher odds of asthma compared to non-Hispanic white children. |
278) ht gain (GWG) in Hispanic and Black women compared to non-Hispanic women in Colorado |
279) duced number of CD34+/α6 integrin+ cells compared to non-transgenic (NTg) littermat |
280) (S.Mol) of the hippocampus at 12 months compared to non-transgenic (non-Tg) animal |
281) y of life is lower for people with autism compared to people without autism, and tha |
282) m experience a much lower quality of life compared to people without autism. |
283) ther enhancement in drug dissolution when compared to plain drug and marketed tablet |
284) eability coefficient (Papp) from S-SNEDDS compared to plain drug. |
285) Compared to previous research on adults wi |
286) ically changing sets of problem instances compared to previous approaches. |
287) ker) aggravated stress ulcer formation as compared to vehicle treated CRS exposed ra |
288) x and GSH and elevations in brain MDA, as compared to vehicle treated CRS rats. |
289) er numbers of previous sexual assaults as compared to youth who offended against non |
290) ave higher risk and criminogenic needs as compared to youth who only sexually offend |
291) ic genetic diversity of 0-0.97% for nad1, compared to 0-0.42% for ITS-2. |
292) ients, 29 % (n = 5) of asthma patients compared to 0.05 % (n = 1) of the contr |
293) ucing memory impairment in rats (2 mg/kg) compared to 0.5 or 1 mg/kg dose. |
294) ated in 11.6% of the homeless population, compared to 0.7% in the BGPS. |
295) orted experiencing gender discrimination, compared to 0.9% among men. |
296) as 21.1 and 28.4% in the US respectively, compared to 11.5 and 12.9% in MX (p < 0 |
297) side effects and treatment outcomes were compared to 14 contemporary control patien |
298) .5% and 19.2% mortality, respectively, as compared to 14.2% and 10% in groups that w |
299) ield and shikonin contents were obtained, compared to 16.32 and 1.81 % from a conve |
300) dian DFI for the study group was 185 days compared to 172 days for the control group |
301) quely in 6 to 12 months before death when compared to 18 to 24 months before death. |
302) at 60.1% activation in the same test case compared to 19.2% activation using default |
303) pt levels of all HDACs were found in BUCC compared to 20 normal mucosas, and these w |
304) HLA-B51 was found in 63.0% of BD patients compared to 20.7% of the healthy control s |
305) % of patients who received reconstruction compared to 23.3% in patients who did not |
|